TY - JOUR
T1 - Large-scale evaluation of genetic variants in candidate genes for colorectal cancer risk in the nurses' health study and the health professionals' follow-up study
AU - Hazra, Aditi
AU - Chanock, Stephen
AU - Giovannucci, Edward
AU - Cox, David G.
AU - Niu, Tianhua
AU - Fuchs, Charles
AU - Willett, Walter C.
AU - Hunter, David J.
PY - 2008/2/1
Y1 - 2008/2/1
N2 - Advances in genomics offer new strategies for assessing the association of common genetic variations at multiple loci and risk of many diseases, including colorectal cancer. Low-penetrance alleles of genes in many biological pathways, such as DNA repair, metabolism, inflammation, cell cycle, apoptosis, and Wnt signaling, may influence the risk of nonfamilial colorectal cancer. To identify susceptibility genes for colorectal cancer, we designed a large-scale case-control association study nested within the Nurses' Health Study (190 cases and 190 controls) and the Health Professionals' Follow-up Study (168 cases and 168 controls). We used a custom GoldenGate (Illumina) oligonucleotide pool assay including 1,536 single nucleotide polymorphisms (SNP) selected in candidate genes from cancer-related pathways, which have been sequenced and genotyped in the SNP500Cancer project; 1,412 of the 1,536 (92%) of the SNPs were genotyped successfully within 388 genes. SNPs in high linkage disequilibrium (r 2 ≥ 0.90) with another assayed SNP were excluded from further analyses. As expected by chance (and not significant compared with a corrected Bonferroni P = 0.00004), in the additive model, 11 of 1,253 (0.9%) SNPs had a Ptrend < 0.01 and 38 of 1,253 (3.0%) SNPs had a Ptrend ≥ 0.01 and Ptrend < 0.05. Of note, the MGMT Lys 178Arg (rs2308237) SNP, in linkage disequilibrium with the previously reported MGMT Ile143Val SNP, had an inverse association with colorectal cancer risk (MGMT Lys178Arg: odds ratio, 0.52; 95% confidence interval, 0.35-0.78; unadjusted Ptrend = 0.0003 for the additive model; gene-based test global P = 0.00003). The SNP500Cancer database and the Illumina GoldenGate Assay allowed us to test a larger number of SNPs than previously possible. We identified several SNPs worthy of investigation in larger studies.
AB - Advances in genomics offer new strategies for assessing the association of common genetic variations at multiple loci and risk of many diseases, including colorectal cancer. Low-penetrance alleles of genes in many biological pathways, such as DNA repair, metabolism, inflammation, cell cycle, apoptosis, and Wnt signaling, may influence the risk of nonfamilial colorectal cancer. To identify susceptibility genes for colorectal cancer, we designed a large-scale case-control association study nested within the Nurses' Health Study (190 cases and 190 controls) and the Health Professionals' Follow-up Study (168 cases and 168 controls). We used a custom GoldenGate (Illumina) oligonucleotide pool assay including 1,536 single nucleotide polymorphisms (SNP) selected in candidate genes from cancer-related pathways, which have been sequenced and genotyped in the SNP500Cancer project; 1,412 of the 1,536 (92%) of the SNPs were genotyped successfully within 388 genes. SNPs in high linkage disequilibrium (r 2 ≥ 0.90) with another assayed SNP were excluded from further analyses. As expected by chance (and not significant compared with a corrected Bonferroni P = 0.00004), in the additive model, 11 of 1,253 (0.9%) SNPs had a Ptrend < 0.01 and 38 of 1,253 (3.0%) SNPs had a Ptrend ≥ 0.01 and Ptrend < 0.05. Of note, the MGMT Lys 178Arg (rs2308237) SNP, in linkage disequilibrium with the previously reported MGMT Ile143Val SNP, had an inverse association with colorectal cancer risk (MGMT Lys178Arg: odds ratio, 0.52; 95% confidence interval, 0.35-0.78; unadjusted Ptrend = 0.0003 for the additive model; gene-based test global P = 0.00003). The SNP500Cancer database and the Illumina GoldenGate Assay allowed us to test a larger number of SNPs than previously possible. We identified several SNPs worthy of investigation in larger studies.
UR - http://www.scopus.com/inward/record.url?scp=39449133283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39449133283&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-07-0195
DO - 10.1158/1055-9965.EPI-07-0195
M3 - Article
C2 - 18268114
AN - SCOPUS:39449133283
SN - 1055-9965
VL - 17
SP - 311
EP - 319
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 2
ER -